Skip to main content
. Author manuscript; available in PMC: 2009 Sep 11.
Published in final edited form as: Peptides. 2007 May 6;28(9):1883–1890. doi: 10.1016/j.peptides.2007.04.017

Figure 1.

Figure 1

VIP-CPT conjugate binding. (Top) The ability of (A-NL-K)VIP (■), (A-NL-K)VIP-L2-CPT (●) and (A-NL-K)VIP-L2 (◆) to inhibit specific 125I-VIP binding to T47D and 3T3 cells containing VPAC1-R was determined. (Bottom) The ability of (A-NL-K)VIP (■), (A-NL-K)VIP-L2-CPT (●) and (A-NL-K)VIP-L2 (◆) to inhibit specific 125II-Ro25-1553 binding to SupT1 and 3T3 cells containing VPAC2-R was determined. The mean value ± S.D. of 3 determinations is indicated. This experiment is representative of 4 others